Wolfe Research reiterates Chewy stock rating ahead of earnings

Chewy is scheduled to report Q4 results on March 25; Wolfe Research reiterated an Outperform with a $44 PT and implies Q4 revenue growth of ~0.8% YoY (street ~0.5%) and an EBITDA margin of 4.9% (up 109 bps YoY). Shares have underperformed the S&P 500 by ~28 percentage points since Dec. 10; the company retains roughly $304.9M in buyback authorization and appointed Chris Deppe as CFO. Analyst price targets run from $39 (TD Cowen) to $50 (Mizuho), reflecting mixed views amid macro headwinds and a slow pet-market recovery.

Analysis

Chewy’s strategic push into higher-margin services and owned channels (subscriptions, vet/pharmacy, sponsored inventory) is the lever that can re-rate the stock if execution reduces CAC and raises LTV over 12–24 months. The economics are binary: a sustained 200–300bp improvement in gross margin from mix shift would justify a material multiple expansion, but failure to control marketing intensity will relegate any top-line growth to marginless share gains.

A modest capital-return program and incremental M&A are unlikely to move the needle by themselves; the second-order benefit is optionality — a disciplined finance team can smooth reported EBITDA by shifting investment cadence, which creates short-term volatility around quarterly prints. Watch promotional intensity and inventory days as leading indicators; a jump in promo or inventory implies near-term margin compression and higher working capital needs.

Competitive dynamics favor firms that can monetize captive demand via higher-margin services and embedded recurring fees; that trade makes the advertising/product sponsorship channel disproportionately important and could siphon digital ad dollars away from app-driven user-acquisition platforms. Conversely, large marketplace incumbents retain structural advantages on logistics and bundling that can compress pricing power for single-category specialists if they choose to compete aggressively on price.

Key catalysts are the next several quarterly releases and management’s commentary on investment cadence — changes there reveal whether management prioritizes growth or margin rehabilitation. Tail risks include a macro consumer pullback that disproportionately hits discretionary hard goods and a ramp in competitor promotional intensity; both could reverse any early margin gains within 2–3 quarters.

Key Decisions for Investors

• Long CHWY equity with a 6–12 month horizon: enter on any post-earnings >5% intraday dip. Target 30–40% upside if management signals sustained margin-first cadence; hedge downside by buying 1:1 6–12 month 20% OTM puts, capping net exposure to ~8–10% of notional (expect ~2–3x upside/downside skew if margins reaccelerate).
• Pair trade — long CHWY / short AMZN (smaller notional on AMZN) over 3–9 months: size the short at ~30% of the CHWY long to express a thesis that specialist monetization outperforms broad marketplace share. Close if CHWY fails to show sequential improvement in ad revenue per MAU or if AMZN shows >2% sequential improvement in Prime bundle penetration.
• Options play for asymmetric return: buy CHWY 6–9 month call spreads (e.g., 1x 25–40% OTM depending on current levels) sized to ~3–5% of book. This preserves capital while offering 3–5x upside if margin/recurring-revenue signals accelerate post-earnings; accept total premium loss as max risk.
• Event hedge: buy short-dated puts on retail peers or a consumer discretionary ETF if Chewy signals shift to promotional growth to defend volume — expect correlated downside across specialty retail within 0–3 months. Size to ~25–40% of the directional CHWY long to protect portfolio beta to retail weakness.